351P - Clinical features and treatment outcomes of Waldenstrom macroglobulinemia patients: A single center study

Background

Waldenstrom macroglobulinemia (WM) is a very rare disease. It also known as lymphoplasmacytic lymphoma, a low grade-B cell lymphoproliferative neoplasm characterized by monoclonal IgM gammopathy. The diagnosis of WM is challenging and data regarding clinical features and treatment outcomes in Indonesia is limited. The aim of this study is to investigate clinical features, treatments and outcomes of WM patients in the tertiary referral cancer center in Jakarta, Indonesia.

Methods

This was a retrospective cohort study conducted in outpatient oncology clinic in a tertiary referral cancer center in Jakarta, Indonesia from 2022 until 2023. It included all patients with working diagnosis WM based on Waldenstrom Macroglobulinemia International Workshop Criteria. Demographic data, clinical features, treatments, and outcomes were collected.

Results

We evaluated a total of 8 patients. Most of the patients (62.5%) were male, with mean age 61.1 + 8.6 years old. All patients had symptoms of anemia such weakness, light-headedness, and shortness of breath. Median hemoglobin was 8.46 (6.0 – 13.1) g/dL. Mean immunoglobulin (Ig)M was 3832. Three (37.5%) patients had autoimmune hemolytic anemia (AIHA), and 3 (37.5%) patients had organomegaly. Seventy percent patients received systemic therapy, mostly (66.7%) with Cyclophosphamide Vincristine Prednisone (CVP) regiment. Among those who had systemic therapy, two (33.3%) patients died, and 1 (16.6%) patient transformed into acute myeloid leukemia (AML).

Conclusions

The clinical features of WM were male sex, elderly, anemia, had AIHA, high IgM and organomegaly. Most patients underwent systemic therapy but had unfavorable responses. Further studies should focus on predictors of survival on WM patients.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.